Galectin-3 C-epitope, ANP, PPIA, and albumin function as drug-responsive panel biomarkers and therapeutic targets in aging and pressure overload-induced cardiac hypertrophy
Puja Laxmanrao ShindeiD, Vikas KumariD, Siddhartha SinghiD, K. C. Sivakumar, Rashmi MishraiD
Abstract
Biological aging (BA) and pressure overload-induced cardiac hypertrophy (PO-CH) are marked by myocardial thickening, fibrosis, and functional decline, culminating in an increased risk of heart failure. Effective clinical management requires biomarkers that not only track disease progression but also monitor therapeutic response. Using Amalaki Rasayana (AR), a cardioprotective nutraceutical-based medicine, in rat models of BA and PO-CH, we identified a panel of serum biomarkers whose treatment-induced decline was associated with disease regression. Among them, galectin-3 emerged in both full-length and oligomeric C-epitope cleaved forms, with the latter closely linked to pathological surface remodeling. Treatment with AR and its bioactive component gallic acid (GA) suppressed extracellular galectin-3 C-epitope oligomer accumulation by inhibiting full-length galectin-3 secretion through phosphorylation-dependent mechanisms and promotion of intracellular retention. Concurrently, serum levels of atrial natriuretic peptide (ANP), cyclophilin A (PPIA), and albumin (ALB) were consistently modulated by therapy. Validation in sera from elderly individuals and cardiac hypertrophy patients responding to conventional treatments supported the translational relevance of this biomarker panel. These findings establish a novel, mechanistically grounded biomarker set--galectin-3 C-epitope, ANP, PPIA, and ALB--for monitoring therapeutic response in cardiac hypertrophy, and position AR as a promising medicinal intervention against age- and pressure-induced cardiac pathology. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=87 SRC="FIGDIR/small/657024v3_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@2498d8org.highwire.dtl.DTLVardef@aeb4fcorg.highwire.dtl.DTLVardef@1ec2f9eorg.highwire.dtl.DTLVardef@12a4392_HPS_FORMAT_FIGEXP M_FIG C_FIG HIGHLIGHTSO_LIGalectin-3 C-epitope, ANP, PPIA, and ALB are elevated in aging and pressure overload driven left ventricular hypertrophy. C_LIO_LIAmalaki rasayana (AR) and Gallic Acid (GA) reduce these markers in cardiac tissue and circulation. C_LIO_LIAR and GA inhibit galectin-3 secretion and oligomeric binding to cardiomyocyte surfaces. C_LIO_LIAR and GA regulation predominantly occurs via phosphorylation-dependent cytoplasmic retention of galectin-3. C_LIO_LIThese markers serve as potential therapeutic targets and diagnostic biomarkers. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting Galectin-3 C-epitope oligomers associated maladaptive mechanotransductive signaling in pressure-overload induced left ventricular cardiac hypertrophy
Puja Laxmanrao Shinde, Vikas Kumar, … Rashmi Mishra·bioRxiv·Feb 9, 2026
- The effect of glucagon-like peptide-1 receptor agonist (GLP1RA) on hypertensive-induced heart failure with preserved ejection fraction and hypertensive cardiomyopathy
Z. Y. Zhang, S.-Y. Liao, … J. J. S.-H. Hai·bioRxiv·Feb 12, 2023
- Ophthalmic acid is a bloodborne metabolite that contributes to age-induced cardiomyocyte hypertrophy
Melod Mehdipour, Sang‐Soon Park, … Guo N. Huang·bioRxiv·Aug 8, 2024
- Whole-Blood Transcriptomics Highlights Galectin-1 in Systolic Blood Pressure
Amadou Gaye, Ashton F. Oliver, … Germán Héctor González·bioRxiv·Sep 16, 2026
- Beta-3 Adrenoreceptors protect from hypertrophic remodelling through AMP-Activated Protein Kinase and Autophagy.
E. Dubois-Deruy, R. Gelinas, … J.-L. Balligand·bioRxiv·Jan 14, 2020
- Can elevated plasma Adiponectin and Ghrelin counteract inflammation in the aging heart?
h. nahar, S. Chandan·bioRxiv·Jun 11, 2023